AbbVie (NYSE: ABBV) announced Phase 2 trial results for zumilokibart, an investigational antibody targeting IL-13, in adults with moderate to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE